Eli Lilly and Company (NYSE:LLY) Shares Sold by Oxler Private Wealth LLC

Oxler Private Wealth LLC reduced its position in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 68.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,896 shares of the company’s stock after selling 4,090 shares during the period. Eli Lilly and Company makes up approximately 0.9% of Oxler Private Wealth LLC’s portfolio, making the stock its 22nd largest position. Oxler Private Wealth LLC’s holdings in Eli Lilly and Company were worth $1,105,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Lipe & Dalton purchased a new position in Eli Lilly and Company during the fourth quarter worth about $26,000. Optiver Holding B.V. purchased a new position in Eli Lilly and Company during the third quarter worth about $36,000. St. Johns Investment Management Company LLC raised its holdings in Eli Lilly and Company by 123.3% during the fourth quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after purchasing an additional 37 shares in the last quarter. Family CFO Inc purchased a new position in Eli Lilly and Company during the third quarter worth about $40,000. Finally, O Brien Wealth Partners LLC increased its holdings in Eli Lilly and Company by 70.5% in the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock valued at $44,000 after buying an additional 31 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Down 0.0 %

Shares of LLY traded down $0.26 during mid-day trading on Wednesday, reaching $802.91. The company had a trading volume of 1,755,160 shares, compared to its average volume of 3,005,760. The stock has a market cap of $763.09 billion, a price-to-earnings ratio of 117.74, a price-to-earnings-growth ratio of 1.55 and a beta of 0.37. The firm has a fifty day simple moving average of $762.62 and a 200-day simple moving average of $689.24. Eli Lilly and Company has a fifty-two week low of $419.80 and a fifty-two week high of $816.61. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same quarter last year, the business earned $1.62 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 13.78 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date is Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on LLY. Truist Financial increased their target price on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a report on Wednesday, February 21st. Morgan Stanley increased their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Finally, Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $769.53.

Check Out Our Latest Stock Analysis on LLY

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Recommended Stories

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.